- Home
- EQR vs ILMN Comparison
EQR vs ILMN Comparison
Compare EQR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- ILMN
- Stock Information
- Founded
- EQR 1993
- ILMN 1998
- Country
- EQR United States
- ILMN United States
- Employees
- EQR N/A
- ILMN N/A
- Industry
- EQR Real Estate Investment Trusts
- ILMN Medical Specialities
- Sector
- EQR Real Estate
- ILMN Health Care
- Exchange
- EQR Nasdaq
- ILMN Nasdaq
- Market Cap
- EQR 26.7B
- ILMN 13.1B
- IPO Year
- EQR 1993
- ILMN 2000
- Fundamental
- Price
- EQR $67.15
- ILMN $96.14
- Analyst Decision
- EQR Buy
- ILMN Buy
- Analyst Count
- EQR 15
- ILMN 17
- Target Price
- EQR $78.53
- ILMN $124.35
- AVG Volume (30 Days)
- EQR 2.0M
- ILMN 2.4M
- Earning Date
- EQR 08-04-2025
- ILMN 07-31-2025
- Dividend Yield
- EQR 4.12%
- ILMN N/A
- EPS Growth
- EQR 8.50
- ILMN N/A
- EPS
- EQR 2.62
- ILMN N/A
- Revenue
- EQR $3,010,100,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- EQR $5.13
- ILMN N/A
- Revenue Next Year
- EQR $4.31
- ILMN $3.15
- P/E Ratio
- EQR $25.71
- ILMN N/A
- Revenue Growth
- EQR 3.81
- ILMN N/A
- 52 Week Low
- EQR $59.41
- ILMN $68.70
- 52 Week High
- EQR $78.84
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- EQR 47.08
- ILMN 55.14
- Support Level
- EQR $65.71
- ILMN $95.75
- Resistance Level
- EQR $67.32
- ILMN $99.78
- Average True Range (ATR)
- EQR 1.07
- ILMN 3.15
- MACD
- EQR 0.10
- ILMN -0.65
- Stochastic Oscillator
- EQR 60.50
- ILMN 24.97
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.